The effect of 'binge' cocaine administration on the expression of cyclin-dependent kinase 5 and its activator p35 in various regions of rat brain.
The present study was aimed at determining whether the administration of cocaine in 'binge' pattern regimen that evoked tolerance to the locomotor stimulant effects of cocaine also influenced the expression of cyclin-dependent kinase 5 (Cdk5) and its activator p35 in the amygdala, medial prefrontal cortex, nucleus accumbens septi and caudate-putamen. Western blot techniques revealed that acute and repeated 'binge' cocaine decreased expression of the Cdk5 protein in the amygdala. In the medial prefrontal cortex, only exposure to repeated 'binge' cocaine decreased the content of the Cdk5 protein. 'Binge' cocaine administration also altered the expression of Cdk5 activator p35 protein. In the amygdala, only repeated 'binge' cocaine decreased the expression of p35, while in the medial prefrontal cortex, a decrease was observed after acute and repeated 'binge' cocaine exposure. In neither the nucleus accumbens septi nor the caudate-putamen acute or repeated 'binge' cocaine modified the expression of Cdk5 and p35. The above data indicate that in contrast to sensitizing doses of cocaine, a single and repeated binge of cocaine, which evoked tolerance to its locomotor stimulant effects, decreases expression of Cdk5 and p35 and possibly decreases the efficacy of neurotransmission or induces brain plastic changes regulated by Cdk5 and its activator p35.
Wedzony
Krzysztof
K
Laboratory of Pharmacology and Brain Biostructure, Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343 Kraków, Poland. nfwedzon@if-pan.krakow.pl
Markowicz-Kula
Katarzyna
K
Chocyk
Agnieszka
A
Fijał
Katarzyna
K
Maćkowiak
Marzena
M
D000679:Amygdala / Q000187:drug effects / Q000201:enzymology; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D003042:Cocaine / Q000494:pharmacology*; D019970:Cocaine-Related Disorders / Q000378:metabolism*; D051360:Cyclin-Dependent Kinase 5 / Q000378:metabolism*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D017072:Neostriatum / Q000187:drug effects / Q000201:enzymology; D009419:Nerve Tissue Proteins / Q000378:metabolism*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000201:enzymology; D017397:Prefrontal Cortex / Q000187:drug effects / Q000201:enzymology; D051381:Rats; D017208:Rats, Wistar
D018765:Dopamine Uptake Inhibitors; D009419:Nerve Tissue Proteins; C089495:neuronal Cdk5 activator (p25-p35); D051360:Cyclin-Dependent Kinase 5; C495907:Cdk5 protein, rat; D003042:Cocaine